- All
- Anesthesiology
- Anti-infectives and immunology
- Biologicals
- Blood disorders
- Cardiovascular
- CNS
- Diabetes
- Endocrinology/Sexual health
- Gastrointestinal Diseases
- General modelling
- Lung Diseases
- Methods
- Oncology
- Paediatrics
- Pain
- Peripheral Nervous System
- Safety pharmacology
Grothey A., Hoefman S., Ruppert M., Vis P., Zisowsky J., Cutsem E., Dochy E.v. Fiala-buskies S., Cleton A., Ploeger B. Exploration of efficacious alternative regorafenib regimens to manage hand − foot skin reaction. ESMO, 2019.
Ploeger B., Hoefman S., Ruppert M., Vis P., Zisowsky J., Grothey A., Cutsem E., Dochy E.v., Cleton A. Exploration of alternative regorafenib regimens to manage hand – foot skin reaction. European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer, 2019. [Link to publication]
Berkhout J., Post T.M., Xu L., Zhang L., Wendland J., Faessel H., Vakilynejad M. Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia. PAGE, 2019. [Link to publication]
Dejongh J. Ahsman M.& Snelder N. A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy. PAGE 2019/ IATDMCTS 2019. [Link to publication]
Bosch R., Petrone M.,Hoefman S., Arends R., Vicini P., Snelder N. Integrate QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. WCDT 2019. [Link to publication]
Bosch R., Petrone M., Hoefman S., Arends R., Vicini P., Snelder N. Predicting the effect of GLP-1 agonists on glucose and HbA1c with a 4GI-HbA1c model. ACOP, 2019. [Link to publication]
Berg P.v.d., Post T.M., Gao W., Miller R., Kesisoglou F., Arrington L., Rizk M.L.
Application of a MK-3682 minimal PBPK-PD model to explain discrepancy between enhanced efficacy and PK in the presence of itraconazole. ACoP9, 2018.
Hooijmaijers R., Fidler M., Schoemaker R., Trame M.N., Wang W., Wilkins J., Post T.M. ShinyMixR : A project-centric R / Shiny run management tool for nlmixr. PAGE, 2018. [Link to publication]
Berg P.v.d., Post T.M., Gao W., Miller R., Kesisoglou F., Arrington L., Rizk M.L. An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model for application in hypothesis generation regarding metabolic pathways and perturbations under various conditions. PAGE, 2018. [Link to publication]
Bosch R., Petrone M., Vicini P., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. PAGE, 2018. [Link to publication]
Jongh J. de. 35 years of modelling and simulation as robust tools in drug development From terminal half-life to quantitative and translational systems pharmacology. 22nd MDO / 33rd JSSX, 2018.
Steeg T.J.v., Keunecke A., Fairman D. Development of a mathematical model to elucidate the cross- linking of GSK1995057 and ADAs and binding to TNFR1 receptor – filling the gap between hypothesis and reality. PAGE, 2018. [Link to publication]
Trame M.N., Post T.M. Session 1c: A Perspective on integrating Pharmacometrics and Quantitative Systems Pharmacology characteristics using examples. ACoP9, 2018. [Link to publication]
Post T.M. Application of an iPSP Model with Reduced Mechanistic Detail for a Disease System Analysis applied to Osteoporosis. ACoP9, 2018. [Link to publication]
Fidler M., Wang W., Post T.M., Wilkins J., Schoemaker R., Trame M.N. Tutorial 1: nlmixr: Population Modeling in R. ACoP9, 2018. [Link to publication]